Clinical Trials
Our Research Centers
We offer clinical trial research opportunities at our Queens and Manhattan offices, ensuring convenience for patients across New York City. By participating in these studies, patients gain access to cutting-edge treatments while contributing to advancements in allergy and immunology care.
NOVELTY
Title: Observational study of obstructive lung disease (NOVELTY) – NOVELTY
Sponsor: AstraZeneca
Description: This global observational study aims to better understand and classify severe asthma and COPD, ultimately improving personalized treatments.
PROSE
Title: Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)
Sponsor: Regeneron Pharmaceuticals
Description: This study evaluates the effectiveness of Dupilumab, a monoclonal antibody, in treating chronic sinusitis with nasal polyps.
RAPID
Title: Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
Sponsor: Regeneron
Description: This trial investigates rapid-onset therapies for managing severe allergic reactions, providing faster relief to patients.
GALDERMA
Title: Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Sponsor: Galderma
Description: Focused on skin conditions, this trial evaluates innovative treatments for chronic inflammatory skin issues.
AZ RANS
Title: RANS. Study in Patients with Severe Eosinophilic Asthma and Nasal Polyps. – RANS
Sponsor: AstraZeneca
Description: This trial investigates rapid-onset therapies for managing severe allergic reactions, providing faster relief to patients.
Eosinophilic Esophagitis
Title: Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Sponsor: Regeneron Pharmaceuticals
Description: Aimed at assessing the safety and efficacy of Dupilumab for patients with eosinophilic esophagitis.
ANDHI
Title: A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)
Sponsor: AstraZeneca
Description: This study evaluates the safety and effectiveness of Benralizumab, a monoclonal antibody targeting eosinophils, in reducing exacerbations and improving asthma control in patients with severe, uncontrolled asthma.